Cosentyx® (secukinumab) meets clinical trial endpoints
Cosentyx®, a treatment for an inflammatory disease has met its…
Cosentyx®, a treatment for an inflammatory disease has met its primary endpoints in patients during a Phase III trial.
List view / Grid view
Cosentyx®, a treatment for an inflammatory disease has met its…
Cosentyx®, a treatment for an inflammatory disease has met its primary endpoints in patients during a Phase III trial.
The US Food and Drug Administration (FDA) has given an…
The US Food and Drug Administration (FDA) has given an investigational sickle cell medicine, crizanlizumab (SEG101), Priority Review.
Patient management programs for Sprycel® patients launched...
15 August 2012 | By Bristol-Myers Squibb Company
Patient management programs for Sprycel® patients launched...
Donation of $6.9 million in 2011 to support the HealthWell…
19 January 2012 | By Bristol-Myers Squibb Company
Donation of $6.9 million in 2011 to support the HealthWell Foundation...